New Treatments for Melanoma

Marie-France Demierre; Sandy Allten; Rebecca Brown


Dermatology Nursing. 2005;17(4):287-295. 

In This Article


Keeping ourselves and our patients informed of ongoing phase III trials (see Table 5 ) is in accordance with the National Comprehensive Cancer Network 2004 Melanoma guidelines of care. The results of ongoing phase III vaccine trials will be relevant to the future care of patients with melanoma. While a "magic bullet" (meaning an effective vaccine with a low toxicity that can be given to those at high risk for melanoma, or administered to those with high risk of recurrence of melanoma after surgical resection) has not yet been discovered, prospects of vaccine therapy for melanoma are bright. Continued involvement by physicians and nurses with enrollment of melanoma patients in phase III trials will be invaluable to this ultimate goal.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.